Serial No.: 09/506,011

1. (Twice Amended) A complex comprising a negatively-charged organic complex and a charged antigen, where (A) said organic complex and antigen are electrostatically associated and (B) said complex generates a CTL response when administered to a mammal.

- 2. (Twice Amended) The complex according to claim 1 wherein said antigen is positively charged.
- 3. (Amended) The complex according to claim 2 wherein said antigen is a protein or derivative or equivalent thereof.
- 4. (Twice Amended) The complex according to claim 2 wherein said negatively-charged organic complex is an adjuvant or derivative or equivalent thereof.
- 5. (Twice Amended) The complex according to claim 2 wherein said antigen is a protein or derivative or equivalent thereof and said negatively-charged organic complex is an adjuvant or derivative or equivalent thereof.
- 6. (Twice Amended) The complex according to claim 5 wherein said adjuvant is a naturally negatively charged adjuvant which has been modified to increase the degree of its negative charge.
- 7. (Twice Amended) The complex according to claim 5 wherein said protein is a naturally positively charged protein which has been modified to increase the degree of its positive charge.
- 8. (Twice Amended) The complex according to claim 5 wherein said adjuvant is a naturally negatively charged adjuvant which has been modified to increase the degree of its negative charge and said protein is a naturally positively charged protein which has been modified to increase the degree of its positive charge.
- 9. (Twice Amended) The complex according to claim 5 wherein said adjuvant comprises a saponin.
- 10. (Twice Amended) The complex according to claim 5 wherein said adjuvant is a saponin complex.

Serial No.: 09/506,011

- 11. (Amended) The complex according to claim 10 wherein said saponin complex is ISCOMATRIXTM.
- 12. (Amended) The complex according to claim 5 wherein said adjuvant is comprises a phospholipid.
- 13. (Amended) The complex according to claim 12 wherein said phospholipid is a phosphoglyceride.
- 14. (Amended) The complex according to claim 13 wherein the phosphoglyceride is selected from the group consisting of phosphatidyl inositol, phosphatidyl glycerol, phosphatidic acid and cardiolipin.
- 15. (Amended) The complex according to claim12 wherein said phospholipid is lipid A.
- 16. (Twice Amended) The complex according to claim 15 wherein the lipid A is selected from the group consisting of diphosphoryl lipid A and monophosphoryl lipid A.
- 17. (Twice Amended) The complex according to claim 1 wherein said complex induces a cytotoxic T-lymphocyte response.